Modulation of intestinal inflammation by yeasts and cell wall extracts: Strain dependence and unexpected anti-inflammatory role of glucan fractions

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Jawhara, Samir ^a,b   Habib, Khalid ^a,b   Maggiotto, François ^a,b   Pignede, Georges ^f   Vandekerckove, Pascal ^f   Maes, Emmanuel ^a,e   Dubuquoy, Laurent ^a,b   Fontaine, Thierry ^g   Guerardel, Yann ^a,e   Poulain, Daniel ^a,b,c,d  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c Service de Parasitologie Mycologie   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CNRS   (France)

^f Lesaffre International   (France)

^g INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BETA GLUCAN; CELL EXTRACT; DEXTRAN SULFATE; FUNGAL EXTRACT; INTERLEUKIN 10; MANNOPROTEIN; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; YEAST CELL WALL EXTRACT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CANDIDA ALBICANS; CANDIDIASIS; CELL WALL; COLITIS; CONTROLLED STUDY; DRUG ISOLATION; DRUG PURIFICATION; FEMALE; FUNGAL CELL; FUNGAL COLONIZATION; FUNGAL STRAIN; HISTOPATHOLOGY; MORTALITY; MOUSE; NONHUMAN; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; SCORING SYSTEM; SINGLE DRUG DOSE; STRAIN DIFFERENCE; TREATMENT RESPONSE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BETA-GLUCANS; CANDIDA ALBICANS; CANDIDIASIS; CELL WALL; COMPLEX MIXTURES; FEMALE; INTERLEUKIN-10; INTESTINAL DISEASES; INTESTINES; MICE; MICE, INBRED BALB C; SACCHAROMYCES CEREVISIAE; TUMOR NECROSIS FACTOR-ALPHA;

CANDIDA ALBICANS; MUS; SACCHAROMYCES CEREVISIAE;

EID: 84864414721     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040648     Document Type: Article

References (64)

1. Goldin BR, Gorbach SL,((2008)) Clinical indications for probiotics: an overview. Clin Infect Dis 46 Suppl 2:: S96-100 discussion S144-151.
2. Shanahan F,((2000)) Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 6:: 107-115.
3. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, et al.((1989)) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterology 96:: 981-988.
4. Guslandi M, Giollo P, Testoni PA,((2003)) A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15:: 697-698.
5. Buts JP, De Keyser N,((2010)) Transduction pathways regulating the trophic effects of Saccharomyces boulardii in rat intestinal mucosa. Scand J Gastroenterol 45:: 175-185.
6. Jawhara S, Poulain D,((2007)) Saccharomyces boulardii decreases inflammation and intestinal colonization by Candida albicans in a mouse model of chemically-induced colitis. Med Mycol 45:: 691-700.
7. Murzyn A, Krasowska A, Augustyniak D, Majkowska-Skrobek G, Lukaszewicz M, et al.((2010)) The effect of Saccharomyces boulardii on Candida albicans-infected human intestinal cell lines Caco-2 and Intestin 407. FEMS Microbiol Lett 310:: 17-23.
8. Murzyn A, Krasowska A, Stefanowicz P, Dziadkowiec D, Lukaszewicz M,((2010)) Capric acid secreted by S. boulardii inhibits C. albicans filamentous growth, adhesion and biofilm formation. PLoS One 5:: e12050.
9. Periti P, Tonelli F,((2001)) Preclinical and clinical pharmacology of biotherapeutic agents: Saccharomyces boulardii. J Chemother 13:: 473-493.
10. Sindhu SC, Khetarpaul N,((2002)) Effect of probiotic fermentation on antinutrients and in vitro protein and starch digestibilities of indigenously developed RWGT food mixture. Nutr Health 16:: 173-181.
11. Lourens-Hattingh A, Viljoen BC,((2001)) Growth and survival of a probiotic yeast in dairy products. Food Research International 34:: 791-796.
12. Mitterdorfer G, Mayer HK, Kneifel W, Viernstein H,((2002)) Protein fingerprinting of Saccharomyces isolates with therapeutic relevance using one- and two-dimensional electrophoresis. Proteomics 2:: 1532-1538.
13. van der Aa Kuhle A, Jespersen L,((2003)) The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochrome-c oxidase II gene. Syst Appl Microbiol 26:: 564-571.
14. Martins FS, Nardi RM, Arantes RM, Rosa CA, Neves MJ, et al.((2005)) Screening of yeasts as probiotic based on capacities to colonize the gastrointestinal tract and to protect against enteropathogen challenge in mice. J Gen Appl Microbiol 51:: 83-92.
15. Arnold HM, Micek ST, Shorr AF, Zilberberg MD, Labelle AJ, et al.((2010)) Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:: 361-368.
16. van Nispen tot Pannerden CM, Verbon A, Kuipers EJ,((2011)) Recurrent Clostridium difficile infection: what are the treatment options? Drugs 71:: 853-868.
17. Czerucka D, Piche T, Rampal P,((2007)) Review article: yeast as probiotics - Saccharomyces boulardii. Aliment Pharmacol Ther 26:: 767-778.
18. Guslandi M, Mezzi G, Sorghi M, Testoni PA,((2000)) Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 45:: 1462-1464.
19. Thomas S, Metzke D, Schmitz J, Dorffel Y, Baumgart DC,((2011)) Anti-inflammatory effects of Saccharomyces boulardii mediated by myeloid dendritic cells from patients with Crohn's disease and ulcerative colitis. Am J Physiol Gastrointest Liver Physiol.
20. Avalueva EB, Uspenskii Iu P, Tkachenko EI, Sitkin SI,((2010)) [Use of Saccharomyces boulardii in treating patients inflammatory bowel diseases (clinical trial)]. Eksp Klin Gastroenterol pp. 103-111.
21. Dalmasso G, Cottrez F, Imbert V, Lagadec P, Peyron JF, et al.((2006)) Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes. Gastroenterology 131:: 1812-1825.
22. Samonis G, Falagas ME, Lionakis S, Ntaoukakis M, Kofteridis DP, et al.((2011)) Saccharomyces boulardii and Candida albicans experimental colonization of the murine gut. Med Mycol 49:: 395-399.
23. Canonici A, Siret C, Pellegrino E, Pontier-Bres R, Pouyet L, et al.((2011)) Saccharomyces boulardii improves intestinal cell restitution through activation of the alpha2beta1 integrin collagen receptor. PLoS One 6:: e18427.
24. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder TF, et al.((2011)) IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol 178:: 735-743.
25. Zelante T, De Luca A, Bonifazi P, Montagnoli C, Bozza S, et al.((2007)) IL-23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol 37:: 2695-2706.
26. Cheng SC, van de Veerdonk FL, Lenardon M, Stoffels M, Plantinga T, et al.((2011)) The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans. J Leukoc Biol 90:: 357-366.
27. Sougioultzis S, Simeonidis S, Bhaskar KR, Chen X, Anton PM, et al.((2006)) Saccharomyces boulardii produces a soluble anti-inflammatory factor that inhibits NF-kappaB-mediated IL-8 gene expression. Biochem Biophys Res Commun 343:: 69-76.
28. Reed KL, Fruin AB, Gower AC, Gonzales KD, Stucchi AF, et al.((2005)) NF-kappaB activation precedes increases in mRNA encoding neurokinin-1 receptor, proinflammatory cytokines, and adhesion molecules in dextran sulfate sodium-induced colitis in rats. Dig Dis Sci 50:: 2366-2378.
29. Fidan I, Kalkanci A, Yesilyurt E, Yalcin B, Erdal B, et al.((2009)) Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses 52:: 29-34.
30. Chung YH, Walker ND, McGinn SM, Beauchemin KA,((2011)) Differing effects of 2 active dried yeast (Saccharomyces cerevisiae) strains on ruminal acidosis and methane production in nonlactating dairy cows. J Dairy Sci 94:: 2431-2439.
31. Buts JP, De Keyser N,((2006)) Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 51:: 1485-1492.
32. Lee JN, Lee DY, Ji IH, Kim GE, Kim HN, et al.((2001)) Purification of soluble beta-glucan with immune-enhancing activity from the cell wall of yeast. Biosci Biotechnol Biochem 65:: 837-841.
33. Garner RE, Hudson JA,((1996)) Intravenous injection of Candida-derived mannan results in elevated tumor necrosis factor alpha levels in serum. Infect Immun 64:: 4561-4566.
34. Chen J, Seviour R,((2007)) Medicinal importance of fungal beta-(1→3), (1→6)-glucans. Mycol Res 111:: 635-652.
35. Hashimoto K, Okawa Y, Suzuki K, Okura Y, Suzuki S, et al.((1983)) Antitumor activity of acidic mannan fraction from bakers' yeast. J Pharmacobiodyn 6:: 668-676.
36. Hida S, Miura NN, Adachi Y, Ohno N,((2007)) Cell wall beta-glucan derived from Candida albicans acts as a trigger for autoimmune arthritis in SKG mice. Biol Pharm Bull 30:: 1589-1592.
37. Poulain D, Jouault T,((2004)) Candida albicans cell wall glycans, host receptors and responses: elements for a decisive crosstalk. Curr Opin Microbiol 7:: 342-349.
38. Fradin C, Poulain D, Jouault T,((2000)) beta-1,2-linked oligomannosides from Candida albicans bind to a 32-kilodalton macrophage membrane protein homologous to the mammalian lectin galectin-3. Infect Immun 68:: 4391-4398.
39. Jawhara S, Thuru X, Standaert-Vitse A, Jouault T, Mordon S, et al.((2008)) Colonization of mice by Candida albicans is promoted by chemically induced colitis and augments inflammatory responses through galectin-3. J Infect Dis 197:: 972-980.
40. Jawhara S, Mogensen E, Maggiotto F, Fradin C, Sarazin A, et al.((2012)) A murine model of dextran sulfate sodium-induced colitis reveals Candida glabrata virulence and contribution of beta-Mannosyltransferases. J Biol Chem In press.
41. Thornton BP, Vetvicka V, Pitman M, Goldman RC, Ross GD,((1996)) Analysis of the sugar specificity and molecular location of the beta-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J Immunol 156:: 1235-1246.
42. Brown GD, Gordon S,((2001)) Immune recognition. A new receptor for beta-glucans. Nature 413:: 36-37.
43. Sener G, Sert G, Ozer Sehirli A, Arbak S, Uslu B, et al.((2006)) Pressure ulcer-induced oxidative organ injury is ameliorated by beta-glucan treatment in rats. Int Immunopharmacol 6:: 724-732.
44. Goodridge HS, Simmons RM, Underhill DM,((2007)) Dectin-1 stimulation by Candida albicans yeast or zymosan triggers NFAT activation in macrophages and dendritic cells. J Immunol 178:: 3107-3115.
45. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, et al.((2007)) Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol 8:: 31-38.
46. Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, et al.((2007)) Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol 8:: 39-46.
47. Bonifazi P, Zelante T, D'Angelo C, De Luca A, Moretti S, et al.((2009)) Balancing inflammation and tolerance in vivo through dendritic cells by the commensal Candida albicans. Mucosal Immunol 2:: 362-374.
48. Driscoll M, Hansen R, Ding C, Cramer DE, Yan J,((2009)) Therapeutic potential of various beta-glucan sources in conjunction with anti-tumor monoclonal antibody in cancer therapy. Cancer Biol Ther 8:: 218-225.
49. Ishibashi K, Miura NN, Adachi Y, Ogura N, Tamura H, et al.((2002)) Relationship between the physical properties of Candida albicans cell well beta-glucan and activation of leukocytes in vitro. Int Immunopharmacol 2:: 1109-1122.
50. Hetland G, Ohno N, Aaberge IS, Lovik M,((2000)) Protective effect of beta-glucan against systemic Streptococcus pneumoniae infection in mice. FEMS Immunol Med Microbiol 27:: 111-116.
51. Li J, Li DF, Xing JJ, Cheng ZB, Lai CH,((2006)) Effects of beta-glucan extracted from Saccharomyces cerevisiae on growth performance, and immunological and somatotropic responses of pigs challenged with Escherichia coli lipopolysaccharide. J Anim Sci 84:: 2374-2381.
52. Liang J, Melican D, Cafro L, Palace G, Fisette L, et al.((1998)) Enhanced clearance of a multiple antibiotic resistant Staphylococcus aureus in rats treated with PGG-glucan is associated with increased leukocyte counts and increased neutrophil oxidative burst activity. Int J Immunopharmacol 20:: 595-614.
53. Forsyth CB, Mathews HL,((2002)) Lymphocyte adhesion to Candida albicans. Infect Immun 70:: 517-527.
54. Rousseau V, Lepargneur JP, Roques C, Remaud-Simeon M, Paul F,((2005)) Prebiotic effects of oligosaccharides on selected vaginal lactobacilli and pathogenic microorganisms. Anaerobe 11:: 145-153.
55. Buddington KK, Donahoo JB, Buddington RK,((2002)) Dietary oligofructose and inulin protect mice from enteric and systemic pathogens and tumor inducers. J Nutr 132:: 472-477.
56. Gastebois A, Mouyna I, Simenel C, Clavaud C, Coddeville B, et al.((2010)) Characterization of a new beta(1-3)-glucan branching activity of Aspergillus fumigatus. J Biol Chem 285:: 2386-2396.
57. Sendid B, Dotan N, Nseir S, Savaux C, Vandewalle P, et al.((2008)) Antibodies against glucan, chitin, and Saccharomyces cerevisiae mannan as new biomarkers of Candida albicans infection that complement tests based on C. albicans mannan. Clin Vaccine Immunol 15:: 1868-1877.
58. Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, et al.((2005)) A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med 202:: 597-606.
59. Hilenski LL, Naider F, Becker JM,((1986)) Polyoxin D inhibits colloidal gold-wheat germ agglutinin labelling of chitin in dimorphic forms of Candida albicans. J Gen Microbiol 132:: 1441-1451.
60. Martins FS, Veloso LC, Arantes RM, Nicoli JR,((2009)) Effects of yeast probiotic formulation on viability, revival and protection against infection with Salmonella enterica ssp. enterica serovar Typhimurium in mice. Lett Appl Microbiol 49:: 738-744.
61. Sendid B, Francois N, Standaert A, Dehecq E, Zerimech F, et al.((2007)) Prospective evaluation of the new chromogenic medium CandiSelect 4 for differentiation and presumptive identification of the major pathogenic Candida species. J Med Microbiol 56:: 495-499.
62. Edwards-Ingram L, Gitsham P, Burton N, Warhurst G, Clarke I, et al.((2007)) Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol 73:: 2458-2467.
63. Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, et al.((2001)) Adenosine kinase inhibitor GP515 improves experimental colitis in mice. J Pharmacol Exp Ther 296:: 99-105.
64. Gillum AM, Tsay EY, Kirsch DR,((1984)) Isolation of the Candida albicans gene for orotidine-5′-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations. Mol Gen Genet 198:: 179-182.